Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights

BACKGROUND: Siponimod (BAF312), a selective S1P(1)/S1P(5) agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P(1)/S1P(5)-dependent anti-inflammatory and pro-myelination effects on CNS-resident cells. OBJECTIVE: Generate preclinical evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigaud, Marc, Rudolph, Bettina, Briard, Emmanuelle, Beerli, Christian, Hofmann, Andreas, Hermes, Erwin, Muellershausen, Florian, Schubart, Anna, Gardin, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573504/
https://www.ncbi.nlm.nih.gov/pubmed/34777855
http://dx.doi.org/10.1177/20552173211049168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573504/
https://www.ncbi.nlm.nih.gov/pubmed/34777855
http://dx.doi.org/10.1177/20552173211049168

Ejemplares similares